BioSpace News Archive

Helius Medical Technologies, Inc. today announced preliminary, unaudited results for the quarter and full year ended December 31, 2022.

Artemetrx®, the industry’s most preeminent platform for integrated drug cost management, is now even more robust with the launch of its new module, Artemetrx Extend™.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of Duchenne muscular dystrophy (Duchenne) is now active and recruiting patients.

iSpecimen Inc. today announced that Tracy Curley, CEO of iSpecimen, will participate in the Sequire Biotechnology Conference to be held virtually on Thursday, February 2, 2023.

Crown Aesthetics, a Crown Laboratories, Inc. company, is excited to announce the launch of BIOJUVE ™ , a novel skin biome brand that uses a clinically-proven, living microbe technology to optimize the overall skin biome and lead to healthier, younger-looking skin.

Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate’s Board of Directors.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today announced the appointment of Devin Smith as the company’s first General Counsel and Chief Compliance Officer.

Catalyst Pharmaceuticals, Inc. today announced that it has received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Teva Pharmaceuticals, Inc. (“Teva”) advising that Teva had submitted an Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE® in the United States.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental new drug application for AYVAKIT ® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM)

TheracosBio today announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy™ (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor.